查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1599359

外阴痛治疗市场：按类型、适应症、提供者分类 - 全球预测 2025-2030

Vulvodynia Treatment Market by Type (Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment), Indication (Generalized Vulvodynia, Localized Vulvodynia), Providers - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

外阴疼痛治疗市场2023年估值为555.3亿美元，预计到2024年将达到608.2亿美元，复合年增长率为9.62%，预计到2030年将达到1056.7亿美元。

外阴痛是一种影响外阴的慢性疼痛状况，有多种治疗选择，从药物、物理治疗到手术介入。有效外阴痛治疗的需求源自于外阴痛对生活品质的严重影响，凸显了对创新和全面解决方案的需求。外阴痛治疗的应用主要针对妇科诊所、医院和专业疼痛管理中心，随着远端医疗和家庭治疗套件的进步扩大了居家医疗的最终用途。外阴痛治疗市场的成长主要受到患者和医疗保健专业人员意识的提高、非侵入性治疗技术的进步以及政府支持政策的影响。药品电子商务的兴起也为分销和患者外展提供了新的途径。最新的潜在治疗机会源于个人化医疗的不断增长的趋势，该趋势侧重于为患者量身定制治疗的基因组方法，以及结合了物理、心理和替代疗法的整体治疗。然而，这个市场面临阻碍患者转诊和获得治疗的重大限制，包括诊断不足、社会耻辱和全科医生知识有限。价格敏感性和某些治疗方法缺乏保险覆盖也构成了市场渗透挑战。预计成长的创新和研发领域包括非阿片类止痛药的开发、雷射疗法的进步以及数位健康工具，例如用于患者管理和教育的应用程式。这些创新可以提高患者的依从性和治疗结果。市场动态是动态的，患者对侵入性较小、更有效的治疗的需求也在不断变化。希望进入或扩展该市场的公司应专注于与医疗保健提供者合作、投资于患者教育计划以及培育社区支持网络，以减少社会障碍并改善获得护理的机会。

主要市场统计
基准年[2023] 555.3亿美元
预测年份 [2024] 608.2亿美元
预测年份 [2030] 1056.7亿美元
复合年增长率（%） 9.62%

市场动态：快速发展的外阴痛治疗市场的关键市场洞察

供需的动态交互作用正在改变外阴痛治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 提高临床医生，特别是妇科医生对外阴百日菊诊断的认识
    • 医疗保健设施和诊断服务的发展
    • 增加研发活动
  • 市场限制因素
    • 原因未知，诊断选择有限。
  • 市场机会
    • 医生提供的外阴自我护理和治疗
    • 仿单标示外疗法的长期可用性
  • 市场挑战
    • 医疗保健提供者对外阴痛缺乏了解

波特的五力：驾驭外阴痛治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外阴痛治疗市场的外在影响

外部宏观环境因素在塑造外阴痛治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解外阴痛治疗市场的竞争状况

对外阴痛治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵外阴痛治疗市场供应商的绩效评估

FPNV 定位矩阵是评估外阴痛治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製外阴痛治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，外阴痛治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 临床医生，尤其是妇科医师对外阴痛诊断的了解不断增加
      • 医疗保健设施和诊断服务的发展
      • 增加研发活动
    • 抑制因素
      • 原因未知，诊断选项有限
    • 机会
      • 医生提供外阴痛的自我护理和治疗
      • 长期供应仿单标示外药品
    • 任务
      • 医疗保健专业人员对外阴痛的了解有限
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章外阴疼痛治疗市场：依类型

  • 生物回馈疗法和物理治疗
  • 病灶内注射
  • 口服治疗
  • 手术治疗
  • 局部治疗

第七章外阴痛治疗市场（依适应症）

  • 全身性外阴痛
  • 局部外阴痛

第八章外阴痛治疗市场（依提供者划分）

  • 医院和护理提供者
  • 製药和生物技术公司
  • 研发中心

第九章 北美及南美外阴痛治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区外阴痛治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的外阴痛治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amneal Pharmaceuticals, Inc.
  • Cipla Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Inc.
  • GTO Pharmaceutical, LLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • VuVatech LLC
  • Zydus Lifesciences Limited
Product Code: MRR-433BAD49EE73

The Vulvodynia Treatment Market was valued at USD 55.53 billion in 2023, expected to reach USD 60.82 billion in 2024, and is projected to grow at a CAGR of 9.62%, to USD 105.67 billion by 2030.

Vulvodynia is a chronic pain condition affecting the vulva, with numerous treatment options ranging from medications and physical therapy to surgical interventions. The necessity for effective vulvodynia treatments stems from its profound impact on the quality of life, emphasizing the need for innovative and comprehensive solutions. The applications of vulvodynia treatments are primarily targeted towards gynecological clinics, hospitals, and specialty pain management centers, with increasing end-use scope in home care settings owing to advancements in telemedicine and home-treatment kits. Market growth for vulvodynia treatments is primarily influenced by increasing awareness among patients and healthcare professionals, technological advancements in non-invasive treatments, and supportive government policies. The rise of e-commerce in pharmaceuticals also provides new avenues for distribution and patient outreach. Latest potential opportunities lie in personalized medicine, focusing on genomic approaches to tailor treatments for patients, and the growing trend of holistic treatments combining physical, psychological, and alternative therapies. However, the market faces significant limitations, including underdiagnosis, social stigma, and limited knowledge among general practitioners, which can hinder patient referrals and access to treatment. Price sensitivity and lack of insurance coverage for certain therapies can also pose challenges to market penetration. Innovation and research areas poised for growth include the development of non-opioid analgesics, advancements in laser therapies, and digital health tools such as apps for patient management and education. These innovations can enhance patient adherence and treatment outcomes. The nature of the vulvodynia treatment market is dynamic, driven by evolving patient demands for less invasive and more effective treatments. Companies looking to enter or expand in this market should focus on partnerships with healthcare providers, investing in patient education programs, and fostering community support networks to mitigate social barriers and improve treatment accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 55.53 billion
Estimated Year [2024] USD 60.82 billion
Forecast Year [2030] USD 105.67 billion
CAGR (%) 9.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vulvodynia Treatment Market

The Vulvodynia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynecologists
    • Developments in healthcare facilities and diagnostic services
    • Increase in the number of research and development activities
  • Market Restraints
    • Unidentified causes and limited diagnosis options
  • Market Opportunities
    • Doctors offering self-care and treatments for vulvodynia
    • Prolonged availability of off-label drugs
  • Market Challenges
    • Limited familiarity of health care providers with vulvodynia

Porter's Five Forces: A Strategic Tool for Navigating the Vulvodynia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vulvodynia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vulvodynia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vulvodynia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vulvodynia Treatment Market

A detailed market share analysis in the Vulvodynia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vulvodynia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vulvodynia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vulvodynia Treatment Market

A strategic analysis of the Vulvodynia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vulvodynia Treatment Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals, Inc., Cipla Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Inc., GTO Pharmaceutical, LLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries Ltd., Upsher-Smith Laboratories, LLC, VuVatech LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vulvodynia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment, Surgical Treatment, and Topical Treatments.
  • Based on Indication, market is studied across Generalized Vulvodynia and Localized Vulvodynia.
  • Based on Providers, market is studied across Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies, and Research & Development Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynecologists
      • 5.1.1.2. Developments in healthcare facilities and diagnostic services
      • 5.1.1.3. Increase in the number of research and development activities
    • 5.1.2. Restraints
      • 5.1.2.1. Unidentified causes and limited diagnosis options
    • 5.1.3. Opportunities
      • 5.1.3.1. Doctors offering self-care and treatments for vulvodynia
      • 5.1.3.2. Prolonged availability of off-label drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited familiarity of health care providers with vulvodynia
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vulvodynia Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Biofeedback & Physical Therapy
  • 6.3. Intralesional Injections
  • 6.4. Oral Treatment
  • 6.5. Surgical Treatment
  • 6.6. Topical Treatments

7. Vulvodynia Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Generalized Vulvodynia
  • 7.3. Localized Vulvodynia

8. Vulvodynia Treatment Market, by Providers

  • 8.1. Introduction
  • 8.2. Hospitals & Care Providers
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Research & Development Centres

9. Americas Vulvodynia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vulvodynia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vulvodynia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals, Inc.
  • 2. Cipla Ltd.
  • 3. Eli Lilly and Company
  • 4. GlaxoSmithKline PLC
  • 5. Glenmark Pharmaceuticals Inc.
  • 6. GTO Pharmaceutical, LLC
  • 7. Hikma Pharmaceuticals PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Taro Pharmaceutical Industries Ltd.
  • 12. Upsher-Smith Laboratories, LLC
  • 13. VuVatech LLC
  • 14. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VULVODYNIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. VULVODYNIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VULVODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VULVODYNIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY BIOFEEDBACK & PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INTRALESIONAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GENERALIZED VULVODYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LOCALIZED VULVODYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY RESEARCH & DEVELOPMENT CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 147. VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023